Alcidion Group Ltd (ASX: ALC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Alcidion Group Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $67.12 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 1.34 billion
Earnings per share -0.004
Dividend per share N/A
Year To Date Return -33.33%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Alcidion Group Ltd (ASX: ALC)
    Latest News

    a woman
    Speculative

    10 small cap ASX shares with enormous potential

    LiveTiles Ltd (ASX:LVT) and Volpara Health Technologies Ltd (ASX:VHT) are two of ten small cap ASX shares that I think investors…

    Read more »

    a woman
    Share Market News

    5 stocks to buy under $5

    Just $5,000 could get you at least 1,000 shares in any of these companies.

    Read more »

    a woman
    Speculative

    3 exciting ASX small cap tech shares to watch in 2020

    Alcidion Group Ltd (ASX:ALC) and two other ASX small cap tech shares could be great long term investments...

    Read more »

    a woman
    Share Gainers

    Why Alcidion, Helloworld, Nearmap, & Wattle Health shares surged higher today

    The Helloworld Travel Ltd (ASX:HLO) share price and the Nearmap Ltd (ASX:NEA) share price are two of four surging notably…

    Read more »

    a woman
    Share Gainers

    Alcidion share price jumps 14% higher on Healthscope deal

    The Alcidion Group Ltd (ASX:ALC) share price has climbed higher after announcing a deal with Healthscope...

    Read more »

    a woman
    Speculative

    3 small cap ASX healthcare shares which could be destined for big things

    Volpara Health Technologies Ltd (ASX:VHT) shares are one of three that I think could have very big futures in the healthcare…

    Read more »

    a woman
    Speculative

    3 exciting small cap ASX shares to watch in 2020

    Alcidion Group Ltd (ASX:ALC) shares are one of three that small cap investors might want to watch closely in FY…

    Read more »

    a woman
    Share Gainers

    Alcidion share price rockets higher after delivering strong revenue growth in FY 2019

    The Alcidion Group Ltd (ASX:ALC) share price has rocketed higher on Thursday after delivering strong sales growth in FY 2019...

    Read more »

    a woman
    Share Market News

    Senetas share price lower as it swings to small loss

    Senetas Corporation Limited (ASX: SEN) provides cyber-security services.

    Read more »

    a woman
    Speculative

    3 small cap ASX shares that could be long-term market beaters

    Audinate Group Limited (ASX:AD8) shares are one of three that I think small cap investors ought to watch very closely...

    Read more »

    a woman
    Speculative

    3 small cap ASX healthcare shares which could have big futures

    Telix Pharmaceuticals Ltd (ASX:TLX) shares are one of three to watch at the small end of the healthcare sector...

    Read more »

    a woman
    Share Market News

    This is why the Livehire results could disappoint investors

    The LiveHire Ltd (ASX: LVH) share price has been falling in 2019.

    Read more »

    Frequently Asked Questions

    No, Alcidion does not pay dividends at this time.

    Alcidion listed on the ASX on 24 June 2011.

    ALC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Alcidion Group Ltd

    Alcidion Group Ltd (ASX: ALC) is a provider of intelligent informatics software for the healthcare sector.

    The company builds, sells, delivers, runs, and supports solutions for healthcare providers. These include clinical, analytical, managerial, and administrative systems.

    Its products include its Miya suite, a Fast Healthcare Interoperability Resources (FHIR) system that allows comprehensive healthcare data to be exchanged between different computer systems.  Other products include Smartpage and Patientrack software.

    Alcidion derives the majority of its revenue from its Australia/New Zealand segment and also has a presence in the United Kingdom.

    ALC Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    27 Mar 2024 $0.05 $0.00 0.00% 206,294 $0.05 $0.05 $0.05
    26 Mar 2024 $0.05 $0.00 0.00% 279,304 $0.05 $0.05 $0.05
    25 Mar 2024 $0.05 $0.00 0.00% 1,468,689 $0.05 $0.05 $0.05
    22 Mar 2024 $0.05 $0.00 0.00% 138,934 $0.05 $0.05 $0.05
    21 Mar 2024 $0.05 $0.00 0.00% 1,627,745 $0.05 $0.05 $0.05
    20 Mar 2024 $0.05 $0.00 0.00% 446,077 $0.05 $0.05 $0.05
    19 Mar 2024 $0.05 $0.00 0.00% 1,041,079 $0.05 $0.05 $0.05
    18 Mar 2024 $0.05 $0.00 0.00% 402,080 $0.05 $0.05 $0.05
    15 Mar 2024 $0.05 $0.00 0.00% 841,226 $0.05 $0.05 $0.05
    14 Mar 2024 $0.05 $0.00 0.00% 1,051,674 $0.05 $0.05 $0.05
    13 Mar 2024 $0.05 $0.00 0.00% 756,594 $0.05 $0.05 $0.05
    12 Mar 2024 $0.05 $0.00 0.00% 544,023 $0.05 $0.05 $0.05
    11 Mar 2024 $0.05 $0.00 0.00% 1,486,803 $0.05 $0.05 $0.05
    08 Mar 2024 $0.05 $0.00 0.00% 1,441,420 $0.05 $0.05 $0.05
    07 Mar 2024 $0.05 $0.00 0.00% 1,870,607 $0.05 $0.05 $0.05
    06 Mar 2024 $0.05 $0.00 0.00% 2,662,847 $0.05 $0.05 $0.05
    05 Mar 2024 $0.05 $0.00 0.00% 1,239,433 $0.05 $0.05 $0.05
    04 Mar 2024 $0.05 $0.00 0.00% 716,008 $0.05 $0.05 $0.05
    01 Mar 2024 $0.05 $0.00 0.00% 878,130 $0.05 $0.05 $0.05
    29 Feb 2024 $0.05 $0.01 22.22% 2,840,357 $0.05 $0.05 $0.04
    28 Feb 2024 $0.05 $0.00 0.00% 7,063,784 $0.05 $0.05 $0.04
    27 Feb 2024 $0.05 $0.00 0.00% 2,507,214 $0.05 $0.05 $0.05

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    05 Sep 2023 Victoria Weekes Buy 100,000 $12,000
    On-market trade.
    09 May 2023 Daniel Sharp Buy 210,000 $20,230
    On-market trade.
    05 May 2023 Daniel Sharp Buy 590,000 $55,191
    On-market trade.
    03 May 2023 Rebecca Wilson Buy 250,000 $24,250
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Rebecca Wilson Non-Executive DirectorNon-Executive Chairman Jul 2017
    Ms Wilson is an experienced company director and Board advisor in Australia, UK and US and has more than 25 years of experience working within the healthcare, technology and life science sectors. She provides advice on complex stakeholder communication, issues management, investor and corporate relations, and business strategy to private and public companies, corporations, governments, and asset managers. She has mature governance and risk management experience.
    Mr Simon Chamberlain Non-Executive Director Jul 2019
    Mr Chamberlain is an accomplished executive and business leader, with more than 20 years experience in executive roles at companies including Experian (LON: EXPN), Medibank Private (ASX: MPL), Qantas (ASX:QAN) and MedAdvisor (ASX:MDR). He is currently the Chief Revenue Officer at the high-growth, techenabled residential services business, Detector Inspector, where he runs the sales, marketing, support and strategy functions. Simon has a proven track record for strategic success and commercial growth across a range of industries and markets. Simon led Qantas entrance into the online hotels business, establishing a profitable, high growth new division. At Medibank, Simon had responsibility across customer channels, data and customer experience. Gaining a better understanding of the complex challenges facing the wider health system led to Simons role leading strategy for MedAdvisor, where he supported the global expansion of its health technology business. Simon brings a valuable international perspective and global network to the Alcidion Board, holding executive roles across the US and the UK, where he was a key part of the executive team that sold the Australian start-up, Hitwise, to Experian in 2007. He is also a member of risk committee.
    Ms Victoria Weekes Non-Executive Director Sep 2021
    Ms Weekes is an non-executive director with experience across a diverse range of industries built on a successful executive career in investment markets and financial services. Victorias 30 years of experience in the finance and banking sector includes Csuite roles as a Managing Director at Citigroup and Executive General Manager at Westpac. As the immediate past Chair of the Sydney Local Health District, Victoria has a deep understanding of the healthcare sector where she served as Chair of its Education & Research Committee and Deputy Chair. Recognised for her specialist expertise in risk management and regulation having led organisations through strategic issue management and transformational change, Victoria is Deputy Chair of the ASIC Markets Disciplinary Panel, immediate past Chair of the NSW Treasury Audit & Risk Committee and President of the Financial Services Institute of Australasia (FINSIA). Until recently Victoria was the Deputy Chair of St George Community Housing, NSWs largest non-government community and affordable housing provider and a member of the Council of the State Library of NSW. She is the chairman of risk committee.
    Ms Katrina (Kate) Elizabeth Doyle (Quirke) Chief Executive OfficerExecutive DirectorManaging Director Jul 2018
    Ms Doyle has been CEO of Alcidion since 2018, prior to which she was CEO of MKM Health until it was acquired by Alcidion. She has been involved in large systems procurements and implementations of healthcare information technology across Australia, United Kingdom, New Zealand and Southeast Asia. Her background involves holding leading management roles at some of the largest healthcare software firms where she has had an impact on strategic product direction across
    the health sector and believes astute application of information technology will support the transformation of healthcare delivery worldwide.
    Mr Daniel Sharp Non-Executive Director Sep 2021
    Originally commencing his career as a lawyer,Mr Sharp has over 25 years senior executive experience in investment banking and corporate finance. From 2012-2020, Daniel was an Executive Director of Corporate Finance at Canaccord Genuity where he led dozens of equity capital market transactions and corporate finance advisory projects across the healthcare, life sciences, technologies, financial services and general industrials sectors. Prior to his executive role at Canaccord, Daniel headed the corporate finance division at two of Australias leading independent Investment Banking/Stockbroking firms. Daniel has managed the IPOs, capital raisings and corporate advisory activities for many successful ASX listed companies in the healthcare, technologies and general industrials sectors. He is closely connected to strong networks of institutional, family office and high net worth investors both in Australia and overseas. he is also a member of risk committee.
    Ms Melanie Jaye Leydin Company Secretary Mar 2019
    -
    Melanie Jaye Leydin Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    J P Morgan Nominees Australia Pty Limited 139,803,795 11.02%
    Mr Malcolm Pradhan 134,582,403 10.61%
    Mr Raymond Howard Blight 75,801,020 5.98%
    Citicorp Nominees Pty Limited 58,449,895 4.61%
    Rewmicman Pty Ltd <Smallman Family A/C> 29,810,441 2.35%
    Mrs Katrina Elizabeth Doyle 27,793,199 2.19%
    Caledonia Nominees Pty Ltd <Caledonia A/C> 19,976,377 1.58%
    MNMD Pty Ltd <Quirke Super Fund A/C> 18,668,086 1.47%
    Rangiora-London Pty Limited <Rangiora-London A/C> 9,800,000 0.77%
    Sandhurst Trustees Ltd <Cyan C3G Fund A/C> 9,469,114 0.75%
    Bnp Paribas Noms Pty Ltd <Drp> 9,129,104 0.72%
    Hsbc Custody Nominees (Australia) Limited 8,651,688 0.68%
    Mr Dean Anthony Mackenzie 8,270,080 0.65%
    Mr Paul John Van Dyk 7,277,866 0.57%
    Isle Of Wight Pty Limited <Mackinnon Family A/C> 6,980,867 0.55%
    Emerald Shares Pty Limited <Emerald Unit A/C> 6,850,000 0.54%
    Hudson Retirement Pty Ltd <Seagulls Super A/C> 6,524,244 0.51%
    Mr Vivek Ramakrishnan + Miss Nisha Srinivasan 6,033,121 0.48%
    Superhero Securities Limited <Client A/C> 5,602,157 0.44%
    Beale & Co Pty Ltd 5,066,134 0.40%

    Profile

    since

    Note